載入...
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
BACKGROUND: Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimer’s disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10 mg/day and ran...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2012
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3493328/ https://ncbi.nlm.nih.gov/pubmed/22681723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-5-283 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|